Welcome to our dedicated page for Hypha Labs SEC filings (Ticker: FUNI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hypha Labs, Inc. (OTCQB: FUNI) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer structured insight into Hypha Labs’ business activities in functional mushroom sciences, its Mushroom Accelerator™ systems, MicroPearls™ ingredients, patent strategy, and capital markets activity.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, investors can review narrative business descriptions, risk factors, and financial statements related to Hypha Labs’ development of AI-enabled mushroom cultivation devices, cartridge systems, and ingredient production for consumer and commercial markets. Filings such as Form 8-K, when present, can detail material events, new agreements, or significant corporate updates.
Hypha Labs has also filed a Form 12b-25 (NT 10-K) indicating a delayed filing of its annual report for the fiscal year ended September 30, 2025, citing the need for additional time to complete the audit of its financial statements. Disclosures of this type help readers understand the company’s reporting timeline and context for upcoming financial statements.
On this page, users can also track beneficial ownership and insider activity through Form 3, Form 4, and Form 5 filings when available, as well as proxy statements on Schedule 14A that address governance and executive matters. Stock Titan enhances these documents with AI-powered summaries that explain key sections of lengthy reports, highlight important changes from prior periods, and make complex topics—such as accounting policies or risk disclosures—more accessible. Real-time updates from EDGAR ensure that new Hypha Labs filings, including 10-Ks, 10-Qs, 8-Ks, and any registration statements related to offerings like the company’s disclosed Regulation A+ raise, are quickly reflected and summarized for efficient review.
Hypha Labs, Inc. reported unaudited results for the three months ended December 31, 2025 with no revenue and a net loss of $521,638, an improvement from a $1,339,641 loss a year earlier. Operating expenses fell sharply as prior-period stock-based compensation dropped.
At December 31, 2025, the company had cash of $42,854, negative working capital of $1,006,193, total liabilities of $2,743,090 and a stockholders’ deficit of $2,685,089. Management states these conditions raise substantial doubt about its ability to continue as a going concern.
Hypha has exited cannabis testing and is developing its Hypha Micropearl bioreactor for at-home functional mushroom production. To support this shift, it relies on debt and equity financing, including $57,485 of net proceeds from a Regulation A offering of Series D preferred stock and warrants during the quarter, alongside increased notes and convertible notes payable.
Hypha Labs, Inc. reported that its board has changed the company’s independent auditor for the fiscal year ending September 30, 2026. The board approved the engagement of Astra Audit and Advisory, LLC and dismissed Fruci & Associates II, PLLC as the current auditor.
Fruci’s audit reports for the years ended September 30, 2024 and 2025 contained clean opinions but included explanatory paragraphs and footnotes raising substantial doubt about Hypha Labs’ ability to continue as a going concern. The company states there were no disagreements or reportable events with Fruci, has requested Fruci’s confirming letter to the SEC, and notes it did not consult with Astra on accounting or audit matters before this appointment.
Hypha Labs, Inc. files its annual report describing a full pivot from its former cannabis testing business to developing the Hypha Micropearl accelerator, a home device that produces functional mushroom "Micropearls" in eight days for use in food and beverages. The company targets a share of a functional mushroom market it cites at $34.75 billion in 2024, growing to $65.83 billion by 2030. It has filed two U.S. patent applications around AI-driven mycelium processing and uses the unregistered Micropearls trademark. The report discloses that the auditor has raised substantial doubt about Hypha Labs’ ability to continue as a going concern due to recurring losses and the need for significant additional financing to complete product development and commercialization. As of January 15, 2026, the company had 155,521,825 common shares outstanding, a non-affiliate market value of $3,069,772 as of March 31, 2025, trades on the OTCQB under “FUNI,” and had 15,420,000 options and warrants outstanding under compensation and consulting arrangements.
Hypha Labs, Inc. filed a Form 12b-25 to notify regulators that its Form 10-K for the fiscal year ended September 30, 2025 will be filed late. The company explains that it could not submit the annual report on time because the audit of its financial statements for that fiscal year had not been completed by the close of business on December 29, 2025, the prescribed due date. By filing this notification of late filing, Hypha Labs formally discloses the delay in its audited annual financial report.